Invizius

Invizius develops anti-inflammatory technology to reduce mortality rates among dialysis patients.

Edinburgh, UK

£2.8MTotal raised

Invizius is a medical technology company developing anti-inflammatory treatments to mitigate cardiovascular risks for dialysis patients. Its H-Guard product coats medical filters to prevent adverse immune responses.

Founders

Andy Herbert

CTO

Andy brings biotech founding and board-level experience from roles at AH-Bio and Invizius. He previously held scientific advisory and research positions at Gemini Therapeutics and the University of Edinburgh.

Richard Boyd

CEO

Richard brings biotech and medtech operating experience from leadership roles at Invizius and VueKlar Cardiovascular. He currently focuses on early-stage biotech and medtech venture development.